23:32 , Jun 24, 2019 |  BC Extra  |  Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) said Jean-Paul Kress will take over as CEO from Simon Moroney, who in February announced his decision not to renew his contract as a member of MorphoSys’ management board, on Sept....
23:26 , Jun 21, 2019 |  BC Extra  |  Preclinical News

June 21 Preclinical Quick Takes: AnaptysBio targets PD-1 for immune disease; plus Forty Seven, Homology and moreBy BioCentury Staff

AnaptysBio agonizes PD-1 for inflammatory disease  AnaptysBio Inc. (NASDAQ:ANAB) presented what CEO Hamza Suria called “the first data from anyone on a PD-1 agonist mAb” at the 2019 Federation of Clinical Immunology Societies (FOCiS) meeting...
23:16 , Jun 21, 2019 |  BC Extra  |  Company News

June 21 Company Quick Takes: FDA rejects Daiichi's AML candidate; plus Sanofi, Novartis and more

Complete response letter for Daiichi's quizartinib  Daiichi Sankyo Co. Ltd. (Tokyo:4568) said FDA issued a complete response letter for quizartinib, its candidate to treat relapsed/refractory FLT3-ITD-positive acute myelogenous leukemia (AML). In May, an FDA advisory...
20:47 , Jun 21, 2019 |  BC Extra  |  Clinical News

AnaptysBio shares sag as Sanofi-Regeneron trial stokes IL-33 doubts

A 12% dip in AnaptysBio's share price Friday suggests investors are concerned that a Phase II readout for a rival IL-33 inhibitor could indicate that the drug class may not provide a differentiated clinical benefit...
22:41 , Jun 20, 2019 |  BC Innovations  |  Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

A new crop of companies is creating tools to systematize development of allosteric protein inhibitors, finally moving industry beyond the one-off compounds that have been found by accident. Allosteric pockets on proteins have long been...
22:17 , Jun 20, 2019 |  BC Extra  |  Company News

Gene therapy, vaccines in focus as Sanofi maps out priorities

As Sanofi continues to pull back from diabetes and cardiovascular diseases, the French pharma is turning toward gene therapy and intensifying its focus on vaccines and cancer ahead of this fall’s CEO change. The shift...
19:45 , Jun 18, 2019 |  BC Extra  |  Company News

Google partnership latest in Sanofi's quest to integrate digital throughout its business

Sanofi and Google partnered to launch the virtual Innovation Lab, which will use multiple Google platform technologies to better match patients to existing treatments from the pharma, find new targets, identify alternative opportunities to intervene...
23:33 , Jun 17, 2019 |  BC Extra  |  Company News

Sanofi shies away from neuro gene therapy programs

Changes to two partnerships this year suggest Sanofi is paring down the disease areas in which it wants to deploy gene therapy. The latest came on Monday, when Voyager Therapeutics Inc. (NASDAQ:VYGR) said it and...
21:21 , Jun 14, 2019 |  BioCentury  |  Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
22:01 , Jun 10, 2019 |  BC Extra  |  Company News

Tilos takeout sees Merck tapping TGFβ to solve checkpoint resistance

In its ongoing quest to find combinations for Keytruda pembrolizumab, Merck is acquiring two-year-old Tilos for its ability to modulate TGFβ, a target that’s been gaining interest on the back of clinical data in immuno-oncology,...